Full-Time

Senior Quality Engineer

Noctrix Health

Noctrix Health

51-200 employees

Prescription wearable neuromodulation for RLS.

Compensation Overview

$150k - $180k/yr

+ Annual bonus

Pleasanton, CA, USA

Hybrid

Hybrid position at the Pleasanton headquarters.

Bachelor's

Category
QA & Testing (1)
Required Skills
Quality Assurance (QA)
Risk Management

Get referred to Noctrix Health

See people who can refer or advise you

Requirements
  • A bachelor's degree or higher in Engineering, Life Sciences, Quality, or a related technical discipline.
  • At least 6 years of Quality Engineering experience within the medical device industry.
  • Significant experience supporting new product development and sustaining product changes.
  • Strong working knowledge of FDA Design Control and Quality System requirements, ISO 13485, ISO 14971, risk management, verification and validation, design transfer, and change control.
  • Demonstrated experience serving as a Design Control subject matter expert and advising cross-functional teams on regulatory requirements, company procedures, documentation expectations, and best practices.
  • Experience supporting medical device development and product changes involving hardware, firmware, software, labeling, components, suppliers, and manufacturing updates.
  • Experience owning or managing risk management documentation for Class II or higher medical devices.
  • Experience reviewing or approving Design Control, verification and validation, engineering change, and manufacturing implementation documentation.
  • Experience supporting Design Transfer and manufacturing implementation activities.
  • Experience leading or supporting CAPA and nonconformance investigations, root cause analysis, corrective actions, and effectiveness evaluations.
  • Strong understanding of the relationship between product risk, design controls, manufacturing changes, and regulatory compliance.
  • Strong analytical and problem-solving skills with the ability to identify compliance risks and recommend practical solutions.
  • Excellent technical writing, documentation, facilitation, and communication skills.
  • Strong organizational skills with the ability to independently manage multiple complex priorities.
  • Demonstrated ability to influence and guide cross-functional teams without direct authority.
Responsibilities
  • Serve as the Design Control subject matter expert and advise product teams on the application of Noctrix standard operating procedures, applicable regulatory requirements, and design control best practices.
  • Act as the lead Quality representative for new product development and sustaining product changes involving hardware, firmware, software, labeling, components, suppliers, and related manufacturing updates.
  • Guide project teams through design planning, design inputs, design outputs, design reviews, design verification, design validation, design transfer, design changes, traceability, and risk management activities.
  • Review proposed product changes and advise teams on the appropriate design control, risk management, verification, validation, and documentation requirements.
  • Participate in project planning, design reviews, change reviews, and cross-functional technical discussions as the Quality representative.
  • Provide Quality Engineering guidance on verification and validation strategies, protocols, reports, acceptance criteria, traceability, risk assessments, and change implementation plans.
  • Lead Quality Engineering activities associated with manufacturing updates resulting from new product development and sustaining product changes.
  • Coordinate with Engineering, Operations, Manufacturing, contract manufacturers, suppliers, and external partners to ensure product changes are implemented effectively and compliantly.
  • Support supplier, component, and manufacturing changes that may impact product design, safety, performance, regulatory requirements, or manufacturing implementation.
  • Support CAPA and nonconformance activities, including investigation planning, root cause analysis, corrective action development, implementation, and effectiveness evaluation.
  • Own or support risk management activities and documentation for Class II or higher medical devices.
  • Review and approve design control, verification and validation, engineering change, risk management, and manufacturing implementation documentation.
  • Identify process roadblocks, compliance risks, unclear requirements, and inefficiencies affecting new product development, sustaining activities, and product change implementation.
  • Recommend and support practical improvements to design control, change management, risk management, verification and validation, and product development processes.
  • Serve as a Design Control subject matter expert during internal audits, external audits, certification audits, regulatory inspections, and Quality System readiness activities.
  • Promote consistent application of Design Control and Quality Engineering best practices across the organization.
Desired Qualifications
  • ASQ Certified Quality Engineer, Certified Quality Auditor, or similar professional certification.
  • Experience with therapeutic wearable, connected medical device, or electro-mechanical medical device products.
  • Experience supporting software and firmware development within a medical device Design Control environment.
  • Experience working directly with contract manufacturers and external development partners.
  • Experience supporting FDA inspections, ISO 13485 certification audits, or other regulatory inspections.
  • Experience with supplier quality and component qualification activities.
  • Experience mentoring Quality Engineers or serving as a technical leader within a Quality organization.
  • Experience working within a high-growth medical device organization.

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reported about $24 million annual run-rate revenue before closing, already commercializing.
  • CMS issued dedicated HCPCS codes and payment in 2024, reducing patient access friction.
  • ResMed can cross-sell Nidra through existing sleep clinics, HME partners, and international distribution.

What critics are saying

  • ResMed must integrate Noctrix by late 2026 while preserving sales momentum and reimbursement.
  • RLS prescriptions depend on sleep physicians and HMEs; coverage changes would choke adoption quickly.
  • If Nidra stalls below ResMed's expectations, the asset becomes a small, deprioritized portfolio experiment.

What makes Noctrix Health unique

  • Nidra is FDA De Novo-cleared, drug-free TOMAC for medication-refractory RLS.
  • AASM guidelines recognized peroneal nerve stimulation in 2024, validating Noctrix's mechanism.
  • ResMed completed the $340 million acquisition on June 1, 2026, giving channel reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.